Bluebird bio Inc

Bluebird bio — Investor Day (December 2015)

73 slides from Bluebird bio's investor day presentation, Dec 7, 2015

  1. Slide 1: Transforming the Lives of Patients with Severe Genetic and Rare Diseases

    Transforming the Lives of Patients with Severe Genetic and Rare Diseases Making Hope a Reality Exhibit 99.4

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue

  3. Slide 3: Tonight

    Tonigt Time Slot (EST) Topic Speaker 8:00 — 8:30 p.m. | Cocktail Reception . | Welcome, Agenda sim DeTore, chief financial officer Opening Remarks Nick Leschly, chief bluebird 35 — 9:05 p.m. WD Beta-thalassemia Major David Davidson, M.D., chief medical officer Sickle Cell Disease David Davidson, M.D

  4. Slide 4: bluebird bio: Why We Do What We Do

    bluebird bio: Why We Do What We Do Our Vision – Make Hope a Reality Seeking to transform the lives of patients with severe genetic and rare diseases through the development of innovative gene therapy products. Ethan Cameron Aidan

  5. Slide 5: Figo Ibbrmmatory dernyknaton on in cxobeat

    Figo 1 Ibbrmmatory dernyknaton on in cxobeat AD oe 72 mage, rhe pest gosh. a FS 2] Multiple Myeloma Plasma Cells \ bluebird

  6. Slide 6: TRUE BLUE

    TRUE BLUE Gaining Mc B4-14-011 100000 evento Rea : et Dosing abteh ae # leocs ove coseoees 29 36 43 50 57 G4 71 78 85 Days {9 product infusio Bing 43 get Hoa" 40%), (9.96. HOS (47%) at Simons Months post-drug product infusion » bluebirdbio’

  7. Slide 7: What is Our Mindset?

    What is Our Mindset? Patient centricity across all disciplines Passionate Urgent Humble Patient-Centric Decision Making GT geeks rule – dig deep Data AND product driven Curiousity – no failure in being wrong A’s don’t settle Two ears, one mouth No alligator hands – speak up, step up Leaders galvaniz

  8. Slide 8: The Innovators Dilemma

    The Innovators Dilemma DOWNSIDE RISK & FEAR UPSIDE OPTIMISM & HUNGER “DOWNSIDE RISK OF SUCCESS IS CHOICE” Dissatisfied Optimists (and Paranoid)

  9. Slide 9: Ecosystem Explosion

    Ecosystem Explosion Competition Great For All (Especially Patients) Gene Therapy (20+) CAR/TCR/T Cell (25+) Gene Editing (8+) Mustang Therapeutics CARsgen

  10. Slide 10: Deepening Pipeline

    Deepening Pipeline Product Candidates Prost res| Preclinical Phase 1/2 Phase 2/3 Rights/Partner CNS Diseases Lenti-D™ orto Rare Hemoglobinopathies LentiGlobin” Oncology Five Prime Target Worldwide Kite Pharma HPV-16 E6 TCR Worldwide Viromed Target excluding Korea Other Programs Worldwide » bluebirdb

  11. Slide 11: Asking the Important Questions

    Asking the Important Questions What is the β-thalassemia clinical/regulatory path forward? What is the SCD data telling us? What are you doing to improve your platform? What are you doing to build a sustainable pipeline? What is the plan for oncology/BCMA?

  12. Slide 12: LentiGlobin Clinical Data Update

    LentiGlobin Clinical Data Update Dave Davidson, M.D. Chief Medical Officer

  13. Slide 13: β-thalassemia Major

    β-thalassemia Major

  14. Slide 14: HGB-204 and HGB-205 β-Thalassemia Subjects

    As of October 28, 2015 *reasons for ineligibility: advanced liver disease (n=3), positive HBV serology (n=1) Consented N=27 Ineligible N=4* Stem Cell Mobilization N=23 Transduction in Progress N=2 Transduction Complete N=20 Drug Product Infused N=17 Awaiting Infusion N=3 Apheresis Failure N=1 HGB-20

  15. Slide 15: Demographics for Treated Patients with β-Thalassemia Major

    Parameter Category HGB-204 (N=13) HGB-205 (N=4) Total (N= 17) Gender (n) M 2 2 4 F 11 2 13 Age (yrs) Median (range) 21 (18-35) 18 (16-19) 20 (16-35) Genotype (n) β0/β0 6 0 6 β0/βE 4 3 7 β0/β+ 1 0 1 β+/β+ 1 1 2 β0/βx 1 0 1 Pre-study pRBC transfusion requirements (ml/kg/year) Median (range) 168 (131-2

  16. Slide 16: Safety Profile: No Drug Product-Related Serious Adverse Events

    Incidence of non-hematologic Grade 3-4 AEs, by PT Occurring in ≥ 2 subjects HGB-204 n (%) HGB-205 n (%) Number of subjects 13 4 Stomatitis 9 (69%) 3 (75%) Febrile Neutropenia 7 (54%) 0 Pharyngeal inflammation 4 (31%) 0 Irregular Menses 2 (15%) 0 All AEs consistent with busulfan myeloablative conditi

  17. Slide 17: Engraftment and LVV-Specific Safety

    HGB-204 HGB-205 Follow-up period (months) Median 9 (n = 13) (range 0.2 – 19.1) Median 11.4 (n = 4) (range 1.8 – 21) Neutrophil engraftment Median Day +18 (n = 11) (range 13 - 29) Median Day +16 (n = 4) (range 13 – 28) Platelet engraftment Median Day +30 (n = 10) (range 17 - 39) Median Day +21 (n = 4

  18. Slide 18: Drug Product VCN and VCN in Peripheral Blood Leukocytes After Infusion

    Drug Product VCN and VCN in Peripheral Blood Leukocytes After Infusion As of October 28, 2015. DP VCN for all treated subjects. PBL VCN given for subjects with ≥2 months follow-up DP β0/β0 Non-β0/β0 1.8 1.6 1.4 1.2 1.0 0.8 0.6 0.4 0.2 0.0 5 4 3 2 0 3 6 9 12 15 18 21 1102 1103 1104 1106 1107 1108 110

  19. Slide 19: HbAT87Q Production After Infusion

    HbAT87Q Production After Infusion As of October 28, 2015. Only includes subjects with ≥3 months of follow-up Median HbAT87Q g/dL 3.8 5.4 6.7 4.4 N=9 N=13 N=11 N=5 6.1 N=4 7.8 N=3 β0/β0 Non-β0/β0 1102 1103 1104 1106 1107 1108 1109 1110 1111 1113 1201 1202 1203 11 10 9 8 7 6 5 4 3 2 1 0 HbAT87Q Concen

  20. Slide 20: Ongoing Transfusion Independence in Non-β0/β0 Patients

    Ongoing Transfusion Independence in Patients with Non- β0/β0 Genotypes with at Least 6 Months Follow Up Days Transfusion-Free Months Transfusion-Free* *as of October 28, 2015 for patients in HGB-204 and November 10, 2015 for patients in HGB-205 Subjects with non-β0/β0 genotypes stop transfusions sho

  21. Slide 21: Reduction in pRBC Transfusions in β0/β0 Genotype

    33% to 100% Reduction in pRBC Transfusions Observed in Subjects with β0/β0 Genotype As of October 28, 2015. Subjects with ≥6 m follow-up, shown to latest 3m interval, as of data cut-off. Subjects 1113 & 1115 had <6m follow-up. 52% 47% 33% 100% 1103 1106 1107 1110 Volume Reduced *3-month average numb

  22. Slide 22: Effect of Drug Product VCN on HbAT87Q Expression

    Effect of Drug Product VCN on HbAT87Q Expression

  23. Slide 23: Evolving Clinical and Regulatory Plans

    Pursue CONDITIONAL APPROVAL on the basis of data from ongoing Northstar (HGB-204) & HGB-205 studies Pursue ACCELERATED APPROVAL on the basis of data from planned pivotal HGB-207 & HGB-208 studies EU U.S. Initial U.S. regulatory strategy will focus on non-β0/β0 patients HGB-207 and likely HGB-208 to

  24. Slide 24: Severe Sickle Cell Disease

    Severe Sickle Cell Disease

  25. Slide 25: Why LentiGlobin May Treat Sickle Cell Disease

    polymerization destabilization V F L T bs bs V F L Q bs b-87 Why LentiGlobin May Treat Sickle Cell Disease These data suggest that as little as 3g/dL (~30%) of anti-sickling hemoglobin could be functionally curative LentiGlobin incorporates anti-sickling amino acid found in fetal hemoglobin (glutami

  26. Slide 26: HGB-206 Enrollment Update

    Patients with severe sickle cell disease Open label, multi-center, U.S. based study Increased enrollment target from 8 subjects to 20 subjects to provide additional data and flexibility for regulatory strategy As of November 17, 2015, 11 subjects enrolled; bone marrow harvest completed for four subj

  27. Slide 27: Severe Sickle Cell Disease Treated Patient Demographics

    Severe Sickle Cell Disease Treated Patient Demographics Parameter HGB-205 HGB-206 1204 1301 1303 1306 Gender M F M M Age at enrollment (years) 13 25 42 20 Time since BB305 infusion 13.0 m 3.0 m 5.3 m <1 m SCD Disease History Vaso-occlusive crisis Y Y Y Y Acute chest syndrome Y Y Y Y Tricuspid regurg

  28. Slide 28: Engraftment and Safety Summary

    No replication competent lentivirus detected in any subject to date Integration site analysis shows highly polyclonal repopulation with no clonal dominance detected at any time point No AEs assessed to be related to BB305 drug product Data as of 01 Oct 2015. 1.ANC ≥ 500 for 3 consecutive days; 2. Un

  29. Slide 29: HbAT87Q Production and Globin Change after Infusion

    HbAT87Q Production and Globin Change after Infusion 1301 1303 1204 10 0 10 0 15 0 Months post drug product infusion Hb g/dL 1 2 3 6 9 12 10.9 12.0 10.6 11.4 11.7 9.1 8.5 7.6 5.5 10 8.6 7.8 9.2 8.5 HbAT87Q HbF HbA2 HbS HbA (transfused) 1.0 0.3 8.6 49% Anti-sickling Hemoglobin 16% Anti-sickling Hemogl

  30. Slide 30: Severe SCD: Subject 1204 Free of Transfusions; No Hospitalizations

    Weaned off transfusions Last transfusion on Day + 88 (> 6 months ago) Severe SCD: Subject 1204 Free of Transfusions; No Hospitalizations Transfusions Chronic transfusions Clinical Status Multiple hospitalizations before starting transfusion regimen Pre-Treatment 1 Year After Treatment Data as of Nov

  31. Slide 31: Advancing LentiGlobin in β-thalassemia Major, Building Evidence in Severe SCD

    Advancing LentiGlobin in β-thalassemia Major Building Evidence of Benefit in Severe SCD Early transfusion independence data in patients with non-β0/β0 genotypes driving clinical and regulatory strategy Encouraging early transfusion reduction data in patients with β0/β0 genotype, but more data and lo

  32. Slide 32: Research Platform

    Research Platform Philip Gregory, D. Phil. Chief Scientific Officer

  33. Slide 33: Research Platform and Strategy

    Drive toward sustainable IND engine with ability to feed pipeline for bluebird’s future Research Platform and Strategy mRNA SynBio Lentivirus T Cell HSC Platform T Cell Platform Future Pipeline MegaTALs Strengthening existing platforms HSC Ex Vivo

  34. Slide 34: HSC Platform Research

    HSC Platform Research Enhance therapeutic potential of bluebird’s current clinical programs Leverage technology platform advantage to address additional indications Research Platform and Strategy HSC Ex Vivo T Cell HSC Platform T Cell Platform Future Pipeline mRNA SynBio Lentivirus MegaTALs

  35. Slide 35: Hypothesis: Improving VCN in the Drug Product Should Increase T87Q Levels

    Hypothesis: Improving VCN in the Drug Product Should Increase T87Q Levels and Further Improve Clinical Benefit

  36. Slide 36: Improving VCN in the Drug Product: Identifying Compounds

    Improving VCN in the Drug Product Identifying Compounds that Improve Transduction Goal: Increased VCN via increased transduction efficiency (% HSCs transduced)

  37. Slide 37: Improving VCN in the Drug Product: Selected Compounds

    Improving VCN in the Drug Product Selected Compounds from Screening Results Experiment performed with pre-characterized “hard to transduce” donor HSCs Similar fold improvement in VCN obtained across a wide range of donors, lentiviral vectors and LVV lots Process is well tolerated Standard Conditions

  38. Slide 38: Markedly Increased % Corrected HSCs

    Improving VCN in the Drug Product Markedly Increased % Corrected HSCs % Transduced Cells Standard Conditions Single-cell PCR assay demonstrates marked increase in transduction efficiency Up to ~90% of the cells transduced using most optimized conditions *preliminary research findings

  39. Slide 39: Increased Transduction Efficiency in Long Term HSC Population

    Goal of increased VCN via increased transduction efficiency (% transduced) achieved Legend: Bulk: CD34+ HSC: CD34+CD38LoCD90+CD45RA- Increased Transduction Efficiency Observed in the Most Primitive Long Term HSC Population % Transduced Cells A B + C *preliminary research findings

  40. Slide 40: Improving VCN in the Drug Product Key Takeaways

    Improving VCN in the Drug Product Key Takeaways Several different compounds identified that increase VCN in the drug product (both alone and in combination) Importantly, increased VCN is achieved in part by increasing the number of transduced cells (% HSCs carrying LentiGlobin) Long term HSCs show a

  41. Slide 41: T cell Platform Research

    T cell Platform Research Intensely competitive space but with potential for transformative benefit Opportunity to exploit breadth of bbb technology platforms to potentially create “best in class” differentiated products Research Platform and Strategy HSC Ex Vivo T Cell HSC Platform T Cell Platform F

  42. Slide 42: Manufacturing of an Enhanced CAR T Cell Product by Inhibiting PI3K/AKT Pathway

    Manufacturing of an Enhanced CAR T Cell Product by Inhibiting PI3K / AKT Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells Adoptive Immunotherapy Program: Oral and Poster Abstracts Session: 703. Adoptive Immunotherapy: Poster I Saturday, December 5, 2015,

  43. Slide 43: Example 2: bluebird Gene Editing Approach MegaTAL Technology

    Example 2: bluebird Gene Editing Approach MegaTAL Technology Expertise in homing endonucleases (HE) and MegaTALs Robust nuclease discovery platform, proprietary database, broad IP Multiple advantages of HE and MegaTALs Naturally occurring proteins Highly specific and efficient Compact size Broad ran

  44. Slide 44: MegaTAL Driven Genome Editing Outcomes

    MegaTAL Driven Genome Editing Outcomes

  45. Slide 45: MegaTAL Platform Drives Efficient Gene Disruption

    MegaTAL Platform Drives Efficient Gene Disruption TCRa KO in T cells c - TCRα megaTAL RNA megaTAL megaTAL + Trex2 Efficient megaTAL TCRa gene KO TCRa editing generates more efficacious anti-tumor T cells TCRa KO using bluebird megaTAL platform is fully compatible with current clinic scale process

  46. Slide 46: Improving MegaTAL Design

    Improving MegaTAL Design Density 4 bp DNA cleavage site NON-PROGRAMMABLE 12 bp TAL target recognition 18 bp HE target recognition megaTAL: 30 bp fully programmable DNA sequence recognition wild type HE central-4 targetable sequences Improved megaTAL platform enhances applicability across the univers

  47. Slide 47: Future Pipeline

    Future Pipeline Leverage academic collaborations to drive early innovative science Build on and extend technology platforms Establish a sustainable pipeline Research Platform and Strategy HSC Ex Vivo T Cell Strengthening existing platforms HSC Platform T Cell Platform Future Pipeline mRNA SynBio Len

  48. Slide 48: Leveraging Select Academic Collaborations

    Celgene, bluebird bio, and the Center for Cell and Gene Therapy Combine Strengths and Resources to Develop T-cell Based Therapies for Cancer On March 19, 2013, BCM signed an exclusive multiyear research and collaboration agreement and a platform technology license agreement with Celgene Corporation

  49. Slide 49: Boolean Immunotherapy

    Boolean Immunotherapy Turning a Negative T cell Signal into a Positive One No Tx CTL CTL + IL4/7

  50. Slide 50: MegaTAL Enabled Targeted Gene Addition

    Demonstrates power of megaTAL and AAV platforms – supports NextGen HSC and Cancer Immunotherapy Programs MegaTAL Enabled Targeted Gene Addition Precision Offers Promise of Enhanced Efficacy and Safety

  51. Slide 51: Research Platform and Strategy Key Takeaways

    Research Platform and Strategy Key Takeaways mRNA SynBio Lentivirus T Cell HSC Platform T Cell Platform Future Pipeline MegaTALs Strengthening existing platforms HSC Ex Vivo Powerful research platform with multiple tools and technologies Today highlighted selected efforts to: Enhance the therapeutic

  52. Slide 52: Immuno-Oncology

    Immuno-Oncology Richard Morgan, Ph.D. Vice President, Immunotherapy Rob Ross, M.D. Head of Oncology

  53. Slide 53: BCMA: A Promising Target in Multiple Myeloma

    B cell maturation antigen (BCMA) is a member of the TNF receptor superfamily. BCMA binds B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL). BCMA is expressed by plasma cells and some mature B cells. Mice deficient in BCMA are healthy and have normal numbers of B cells, but

  54. Slide 54: bb2121 Vector Design

    bb2121 Vector Design SP Anti-BCMA scFv CD3z 41BB MND CD8 bb2121 CAR Expression Control CAR Anti-BCMA CAR Anti-BCMA CAR Expression Anti-BCMA CAR – bb2121

  55. Slide 55: Single Treatment with bb2121 CAR T Cells Clears Animals of MM

    Tumor treatment Bortezomib A Single Treatment with bb2121 CAR T Cells Clears Animals of MM and Results in 100% Survival Survival

  56. Slide 56: bb2121 CAR T Cells Infiltrate and Eliminate BCMA+ MM Tumors

    bb2121 CAR T Cells Infiltrate and Eliminate BCMA+ MM Tumors In control mice, the BCMA+ MM tumor expands, and no CD3+ cells infiltrate In bb2121 treated mice, the BCMA+ MM tumor regresses; CD3+ CAR T cells infiltrate and eliminate the tumor Brown staining indicates presence of target protein bb2121 C

  57. Slide 57: An Efficient CAR T Drug Product Manufacturing Process

    (Day 3-10) Expansion (Day 10) Harvest/Cryopreservation (Day -1) Leukapheresis Gene modified T cells infused back to patient (Day 0) PBMC Isolation, Culture Initiation/Activation (Day 1) Transduction with LVV Gene modified T cells Step 1 Step 2 Step 3 Step 4 Treatment An Efficient CAR T Drug Product

  58. Slide 58: Manipulating T Cell Lineages for Improved Anti-Tumor Activity

    Goal: Generate More Efficacious Anti-Tumor T Cells Manipulating T Cell Lineages for Improved Anti-Tumor Activity T Cell Lineages Post-Antigen Stimulation TN Cell TSCM Cell TCM Cell TEM Cell TEFF Cell T Cell Plasticity Self Renewal Long Lived Terminally Differentiated No Self Renewal Short Lived

  59. Slide 59: Improved T Cell Manufacturing

    Improved T Cell Manufacturing IL-2 (standard) IL-2 + PI3K inhibitor IL-7 + IL-15 Stress Test Using Hard To Treat Tumor Models

  60. Slide 60: Stress Test 1: Treating an Aggressive Lymphoma

    Infuse CAR T cells Day 20 after CAR T Day 35 after CAR T Day 15 after CAR T Day 0, Tumor Cells Stress Test 1: Treating an Aggressive Lymphoma with a Minimal Number of bb2121 T Cells IL-2 IL-2 + PI3K IL-7 + IL-15 Vehicle

  61. Slide 61: Stress Test 2: Cancer Relapse Model

    Primary Tumor Treatment Tumor Re-Challenge Re-Challenge With New Tumor Stress Test 2: Use a Cancer Relapse Model as a Measure of bb2121 T Cell Durability and Long-Term Fitness

  62. Slide 62: Deepening Pipeline

    Deepening Pipeline Product Candidates Prost res| Preclinical Phase 1/2 Phase 2/3 Rights/Partner CNS Diseases Lenti-D™ orto Rare Hemoglobinopathies LentiGlobin” Oncology Five Prime Target Worldwide Kite Pharma HPV-16 E6 TCR Worldwide Viromed Target excluding Korea Other Programs Worldwide » bluebirdb

  63. Slide 63: Promising Proof of Concept for bb2121 from NCI

    Promising Proof of Concept for bb2121 from NCI Latebreaker with Other Anti-BCMA CAR T Therapy Data from NCI-sponsored Phase 1 first-in-human study of anti-BCMA CAR T therapy in heavily pre-treated patients with multiple myeloma as presented at ASH 2015 press conference Presenter and PI Jim Kochender

  64. Slide 64: Promising Proof of Concept for bb2121 from NCI

    Promising Proof of Concept for bb2121 from NCI Latebreaker with Other Anti-BCMA CAR T Therapy Data from NCI-sponsored Phase 1 first-in-human study of anti-BCMA CAR T therapy in heavily pre-treated patients with multiple myeloma as presented at ASH 2015 press conference Presenter and PI Jim Kochender

  65. Slide 65: Promising Proof of Concept for bb2121 from NCI

    Promising Proof of Concept for bb2121 from NCI Latebreaker with Other Anti-BCMA CAR T Therapy Data from NCI-sponsored Phase 1 first-in-human study of anti-BCMA CAR T therapy in heavily pre-treated patients with multiple myeloma as presented at ASH 2015 press conference Presenter and PI Jim Kochender

  66. Slide 66: Promising Proof of Concept for bb2121 from NCI

    Promising Proof of Concept for bb2121 from NCI Latebreaker with Other Anti-BCMA CAR T Therapy Data from NCI-sponsored Phase 1 first-in-human study of anti-BCMA CAR T therapy in heavily pre-treated patients with multiple myeloma as presented at ASH 2015 press conference Presenter and PI Jim Kochender

  67. Slide 67: CRB-401 (Refractory Multiple Myeloma): First Oncology Clinical Trial

    U.S.-based, 6-10 clinical sites – including NCI N = 40 patients, standard 3+3 Design based on CAR+ T cells doses Primary endpoint = Determine the maximally tolerated dose and recommended phase 2 dose (RP2D) Subjects must have received 3 prior regimens including a proteasome inhibitor (bortezomib, ca

  68. Slide 68: Differentiated Oncology Approach

    Deliver differentiated, best-in-class, genetically modified cellular products to patients suffering from cancer. Differentiated Oncology Approach BCMA (Partnered with Celgene) HPV Partnered with Kite Five Prime Target Viromed Target LVV Technology Manufacturing Advances (Pl3K) LVV Technology Manufac

  69. Slide 69: Differentiated Oncology Approach

    Deliver differentiated, best-in-class, genetically modified cellular products to patients suffering from cancer. Five Prime Target Viromed Target BCMA (Partnered with Celgene) HPV Partnered with Kite Differentiated Oncology Approach

  70. Slide 70: Closing

    Closing Nick Leschly Chief Bluebird

  71. Slide 71: Asking the Important Questions

    Asking the Important Questions What is the β-thalassemia clinical/regulatory path forward? What is the SCD data telling us? What are you doing to improve your platform? What are you doing to build a sustainable pipeline? What is the plan for oncology/BCMA?

  72. Slide 72: bluebird bio 2020: The Gene Therapy Products Company

    2010 - 2014 bluebird bio 2020: The Gene Therapy Products Company 2015 - 2020 Early POC Clinical Data Infrastructure & Capabilities Core Program Clinical Data Broad Gene Therapy Infrastructure Translational Development Manufacturing Clinical Regulatory Tech & Global Collaborations and New Products Gl

  73. Slide 73: Q&A

    Q&A

bluebird bio — Investor Day (December 2015) on 6ix